Yonsei University · Medicine
Professor Seung Il Kim's research lab specializes in translational oncology and precision medicine, focusing on improving outcomes in breast cancer through innovative biomarker discovery and immune modulation. The lab investigates tumor-derived extracellular vesicles (EVs) and their microRNA cargo as liquid biopsy tools for early cancer detection and monitoring. It also explores the tumor microenvironment, particularly the heterogeneity and exhaustion of CD8+ T cells in tumors and metastatic lymph nodes, to understand immune evasion and improve immunotherapy response. Additionally, the lab develops clinical prediction models, such as nomograms for pathologic complete response in axillary node-positive breast cancer, to guide personalized treatment decisions.
Figures are computed from collected data and may differ slightly.
To increase the pCR rate, type-specific approaches according to subtypes, such as an addition of trastuzumab, increasing the number of cycles or a novel regimen, should be considered.
Extracellular vesicles (EV) have been emerging as potential biomarkers for disease monitoring. In particular, tumor-derived EV (TDE) are known to carry oncogenic miRNA, so they can be used for diagnosis of early cancer by analyzing the expression levels of EV-miRNA circulating in the blood. Here, using our novel microfluidic device, we rapidly and selectively isolate cancerous EV expressing breast cancer-derived surface markers CD49f and EpCAM within 2 minutes. Based on seven candidates of miRNA
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune response in breast cancer, we examined the heterogeneity of CD8<sup>+</sup> T cells in tumors, metastatic lymph nodes (mLNs), and peripheral blood from patients with early breast cancer (<i>n</i> = 131). Among tissue-resident memory CD8<sup>+</sup> T (T<sub>RM</sub>) cells, including virus- and tumor-
To develop a nomogram predicting probability of axillary pathologic complete response (pCR) in patients with cytologically proven axillary node-positive breast cancer who received neoadjuvant chemotherapy (NAC).The current management of axillary intervention in node-positive breast cancer patients who received NAC is axillary lymph node dissection (ALND) regardless of axillary pCR.We reviewed the records of 415 patients with cytologically proven node-positive breast cancer that were treated with
Thermococcus onnurineus NA1, a sulfur-reducing hyperthermophilic archaeon, is capable of H(2)-producing growth, considered to be hydrogenogenic carboxydotrophy. Utilization of formate as a sole energy source has been well studied in T. onnurineus NA1. However, whether formate can be used as its carbon source remains unknown. To obtain a global view of the metabolic characteristics of H(2)-producing growth, a quantitative proteome analysis of T. onnurineus NA1 grown on formate, CO, and starch was
Open papers in the app to read, cite, and organize with AI.
